Request Demo
The positive results of the phase 2b clinical trial for the TYK2TYK2 inhibitor drug TAK-279 have rendered Takeda's acquisition of the drug from Nimbus Therapeutics a prudent decision
22 Mar 2023
·
Investment
·Original
Clinical Study
A few months ago, Takeda paid $4 billion to buy the psoriasis drug TAK-279 from startup Nimbus Therapeutics. Recently, Takeda announces the positive results in Phase 2b study of the drug, at the highest dose of TAK-279, 46% of patients achieved PASI 90 and 33% achieved PASI 100 at 12 Weeks, Indicating a near-total or total clearance of skin lesions. It hasn’t been previously shown with an oral pill and approaches that of more potent injectable drugs.
TAK-279 is one of many medicines in development that target TYK2, an enzyme involved in cell signaling pathways that are implicated in inflammation. These treatments have become highly coveted by drugmakers because of their potential to be oral alternatives to top-selling, injectable medicines like Humira. Last September, the Food and Drug Administration made Sotyku the first TYK2 inhibitor approved, clearing it for psoriasis.
TAK-279 is a small molecule drug developed by Nimbus TherapTYK2cs LLC that targets TYK2, a member of the Janus kinase (JAK) family invinflammation signaling pathways of various cytokines. TAK-279 functions as a TYK2 inhibitor and is being investigated for its potential therapeutic applications in aHumiraune diseases such as pFood and Drug Administrations. This drug aims to inTYK2 inhibitorTYK2upt the JAK/STAT signaling pathway, wpsoriasiss a crucial role in immune cell function and has been implicated in a range of autoimmune diseases. Currently, TAK-279 has reached phase 2 clinical trials, the second highest phase of clinical development. The progress made thus far in developing TAK-279 suggests its potential as a promising therapeutic option for patients with autoimmune diseases.
Psoriasis is a chronic, immune-mediated disorder with cutaneous and systemic manifestations and substantial negative effects on patient quality of life. Psoriasis has a strong, albeit polygenic, genetic basis. Whereas approximately half of the accountable genetic effect of psoriasis maps to the major histocompatibility complex, >70 other loci have been identified, many of which implicate nuclear factor-κB, interferon signalling and the IL-23–IL-23 receptor axis.
Search the drug intelligence database: Synapse, a total of 970 drugs and 3509 clinical trials were found for the treatment of psoriasis. For this indication, the top three research and development organizations are Pfizer, Novartis and Amgen, the major R&D targets are focused on TNF-α、GR and LTα. The top three types of drug development for this indication are Small molecule drug, Monoclonal antibody, and Biosimilar.
FinallPsoriasis
Psoriasisll Evachronic, immune-mediated disordere-Mediated Diseases Including Systemic Lupus Erythematosus (SLE) and Inflammatory Bowel Disease (IBD), anPsoriasis Further Indications in the Future.psoriasisnuclear factor-κBIL-23–IL-23 receptor axis
Organizations
Indications
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.